Celecoxib in Treating Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Studying samples of tissue, blood, and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This clinical trial is studying celecoxib in treating patients with stage I, stage II, or stage IIIA non-small cell lung cancer.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vanderbilt-Ingram Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Celecoxib

Criteria

DISEASE CHARACTERISTICS:

• Presumed histological or cytological diagnosis of non-small cell lung cancer

• Diagnosis to be confirmed upon study entry to collect biopsy material for correlative studies

• Stage I-IIIA disease

PATIENT CHARACTERISTICS:

• ECOG performance status of 0-2

• Serum creatinine ≤ 1.5 mg/dL

• Granulocytes ≥ 1,500/mm^3

• Platelets ≥ 100,000/mm^3

• AST ≤ 3 times normal

• Bilirubin ≤ 1.5 mg/dL

• Not pregnant or nursing

• Fertile patients must use effective contraception

• No active unresolved infection

PRIOR CONCURRENT THERAPY:

• At least 7 days since prior and no concurrent non-steroidal anti-inflammatory agents or other cyclo-oxygenase-2 inhibitors

• At least 7 days since prior parenteral antibiotics

• No prior systemic chemotherapy or radiotherapy